Table 3.

Comparative efficacy of epoetin alfa-epbx and epoetin alfa, evaluated by secondary efficacy end pointsa

End PointsEpoetin alfa-epbx, n=306Epoetin alfa, n=306P Value
Patients with mean weekly hemoglobin level within 9.0−11.0 g/dl at week 24,b n/N (%)188/257 (73.2)185/259 (71.4)0.69
Patients who received a red blood cell transfusion at any time during the 24-wk treatment period,c n/N (%)19/303 (6.3)18/305 (5.9)0.87
  • a Secondary efficacy end points were analyzed using the intent-to-treat population.

  • b Percentages were calculated using the number of observations at week 24 within a treatment group as the denominator.

  • c Percentages were calculated using the number of patients participating in the trial at any time during the treatment period within a treatment group as the denominator.